Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research Report), boosting the price target to $45.00. Mitchell Kapoor’s rating is based on the
Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research Report), boosting the price target to $45.00. Mitchell Kapoor’s rating is based on the
H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Summit Therapeutics to $45 from $30 and keeps a Buy rating on the shares. The firm says the ivonescimab
הפירמה מאמינה שהנתונים החדשים על ivonescimab בטיפול בסרטן ראש וצוואר קרטיני וסרטן המעי הגס מגלים יותר הזדמנויות לשימוש בתרופה, לא רק בסרטן הריאות.
Shares of Instil Bio (TIL) gained nearly 30% on Friday morning after Baird boosted its price target on the stock to $180. The price target raise came a day after
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Moderna (MRNA) expects sales of between $2.5B-$3.5B next year